Fancy bioisosteres: Novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3628-3635

  Schlotter, Karin ^a   Boeckler, Frank ^a   Hübner, Harald ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOFURAN DERIVATIVE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GPCR LIGAND; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL[2,2]PARACYCLOPHANE 4 CARBOXAMIDE; PARACYCLOPHANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCULATION; CHIRALITY; CHO CELL; CONTROLLED STUDY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; ENANTIOMER; MOLECULAR INTERACTION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; BENZENE DERIVATIVES; BENZOFURANS; BINDING SITES; BRIDGED COMPOUNDS; CENTRAL NERVOUS SYSTEM AGENTS; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CRICETULUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; THYMIDINE;

EID: 33745182275     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060138d     Document Type: Article

References (37)

1. Chen, X.; Wang, W. The use of bioisosteric groups in lead optimization. Annu. Rep. Med. Chem. 2003, 38, 333-346.
2. (a) Hübner, H.; Haubmann, C.; Utz, W.; Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D3 subtype. J. Med. Chem. 2000, 43, 756-762.
3. (b) Lenz, C.; Haubmann, C.; Huebner, H.; Boeckler, F.; Gmeiner, P. Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel nonaromatic D3 agonist. Bioorg. Med. Chem. 2005, 13, 185-191.
4. (a) Ortner, B.; Waibel, R.; Gmeiner, P. Indoloparacyclophanes: synthesis and dopamine receptor binding of a novel arylbioisostere. Angew. Chem., Int. Ed. 2001, 40. 1283-1285.
5. (b) Ortner, B.; Hübner, H.; Gmeiner, P. Planar chiral indoles: synthesis and biological effects of the enantiomers. Tetrahedron: Asymmetry 2001, 12, 3205-3208.
6. (a) Bettinetti, L.; Schlotter, K.; Hübner, H.; Gmeiner, P. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J. Med. Chem. 2002, 45, 4594-4597.
7. (b) Boeckler, F.; Leng, A.; Mura, A. Bettinetti, L.; Feldon, J.; Gmeiner, P.; Ferger, B. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice. Biochem. Pharmacol. 2003, 66, 1025-1032.
8. Schlotter, K.; Boeckler, F.; Hübner, H.; Gmeiner, P. Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. J. Med. Chem. 2005, 48, 3696-3699.
9. (a) Rozenberg, V.; Danilova, T. Y.; Sergeeva, E.; Vorontsov, E.; Starikova, Z.; et al. Resolution and novel reactions of 4-hydroxy-[2.2] paracyclophane. Eur. J. Org. Chem. 2002, 468-477.
10. (b) Rozenberg, V.; Bubrovina, N.; Sergeeva, E.; Antonov, D.; Belokon, Y. An improved synthesis of (S)-(+)- and (R)-(-)-[2.2]paracyclophane-4-carboxylic acid. Tetrahedron: Asymmetrt 1998, 9, 653-656.
11. Leopoldo, M.; Berardi, F.; Colabufo, N. A.; De Giorgio, P.; Lacivita, E.; Perrone, R.; Tortorella, V. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 receptor ligands. J. Med. Chem. 2002, 45, 5727-5735.
12. (a) Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L. Simple, efficient catalyst system for the palladium-catalyzed amination of aryl chlorides, bromides, and triflates. J. Org. Chem. 2000, 65, 1158-1174.
13. (b) Hartwig, J. F. Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and Inflates: scope and mechanism. Angew. Chem., Int. Ed. 1998, 37, 2046-2067.
14. (a) Nishiyama, M.; Yamamoto, T.; Koie, Y. Synthesis of N-arylpiperazines from aryl halides and piperazine under a palladium tri-tert-butylphosphine catalyst. Tetrahedron Lett. 1998, 39, 617-620.
15. (b) Torisawa, Y.; Nishi, T.; Minamikawa, J.-i. Progress in arylpiperazine synthesis by the catalytic amination reaction. Bioorg. Med. Chem. 2002, 10, 4023-4027.
16. (a) Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.; Wermuth, C. G.; Schwartz, J.-C.; Everitt, B. J.; Sokoloff, P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999, 400, 371-375.
17. (b) Bezard, E.; Ferry, S.; Mach, U.; Stark, H.; Leriche, L.; Boraud, T.; Gross, C.; Sokoloff, P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9, 762-767.
18. Hayes, G.; Biden, T. J.; Selbie, L. A.; Shine, J. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol. Endocrinol. 1992, 6, 920-926.
19. Sokoloff, P.; Andrieux, M.; Besançon, R.; Pilon, C.; Martres, M.-P.; Giros, B.; Schwartz, J.-C. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur. J. Pharmacol. 1992, 225, 331-337.
20. Asghari, V.; Sanyal, S.; Buchwaldt, S.; Paterson, A.; Jovanovic, V.; Van Tol, H. H. M. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 1995, 65, 1157-1165.
21. (a) Mierau, J.; Schneider, F. J.; Ensinger, H. A.; Chio, C. L.; Lajiness, M. E.; Huff, R. M. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol. 1995, 290, 29-36.
22. (b) Hübner, H.; Kraxner, J.; Gmeiner, P. Cyanoindole derivatives as highly selective dopamine D4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments. J. Med. Chem. 2000, 43, 4563-4569.
23. Chio, C.; Lajiness, M. E.; Huff, R. M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 1994, 45, 51-60.
24. Clark, T.; Alex, A.; Beck, B.; Chandrasekar, J.; Gedeck, P.; Horn, A.; Huttern, M.; Martin, B.; Rauhut, G.; Sauer, W.; Schindler, T.; Steinke, T. VAMP 7.0 Program Package; Oxford Molecular Group Plc.: Oxford, U.K., 1998.
25. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A.7; Gaussian, Inc.: Pittsburgh, PA, 1998.
26. Lenz, C.; Boeckler, F.; Hubner, H.; Gmeiner, P. Analogues of FAUC 73 revealing new insights into the structural requirements of nonaromatic dopamine D3 receptor agonists. Bioorg. Med. Chem. 2004, 12, 113-117.
27. Lenz, C.; Boeckler, F.; Hübner, H.; Gmeiner, P. Fancy bioisosteres: synthesis, SAR, and pharmacological investigations of novel non-aromatic dopamine D3 receptor ligands. Bioorg. Med. Chem. 2005, 13, 4434-4442.
28. Wolinski, K.; Hinton, J. F.; Pulay, P. Efficient implementation of the gauge-independent atomic orbital method for NMR chemical shift calculations. J. Am. Chem. Soc. 1990, 112, 8251-8260.
29. Meyer, E. A.; Castellano, R. K.; Diederich, F. Interactions with Aromatic Rings in Chemical and Biological Recognition. Angew. Chem., Int. Ed. 2003, 42, 1210-1250.
30. Allen, F. H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr., Sect. B 2002, 58, 380-388.
31. PC Spartan Plus, version 1.5; Wave Function, Inc.: Irvine, CA, 1998.
32. SYBYL6.9: Tripos Inc.: St. Louis, MO, 2003.
33. Cram, D. J.; Allinger, N. L. Macro Rings. XII. Stereochemical consequences of steric compression in the smallest paracyclophane. J. Am. Chem. Soc. 1955, 77, 6289-6294.
34. Cram, D. J.; Day, A. C. Macro Rings. XXXI. Quinone derived from [2.2]paracyclophane, an intramolecular-molecular complex. J. Org. Chem. 1966, 31, 1227-1232.
35. Falk, H.; Reich-Rohrwig, P.; Schlogl, K. Absolute configuration and circular dichroism of optically active [2.2]paracyclophane derivatives. Tetrahedron 1970, 26, 511-527.
36. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
37. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.